CN1642543A - 治疗糖尿病性足部感染的噁唑烷酮肠胃外、静脉内和口服给药 - Google Patents

治疗糖尿病性足部感染的噁唑烷酮肠胃外、静脉内和口服给药 Download PDF

Info

Publication number
CN1642543A
CN1642543A CNA038073471A CN03807347A CN1642543A CN 1642543 A CN1642543 A CN 1642543A CN A038073471 A CNA038073471 A CN A038073471A CN 03807347 A CN03807347 A CN 03807347A CN 1642543 A CN1642543 A CN 1642543A
Authority
CN
China
Prior art keywords
diabetic foot
substituted
infection according
foot infection
treating diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038073471A
Other languages
English (en)
Chinese (zh)
Inventor
C·诺顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CN1642543A publication Critical patent/CN1642543A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA038073471A 2002-03-29 2003-03-21 治疗糖尿病性足部感染的噁唑烷酮肠胃外、静脉内和口服给药 Pending CN1642543A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36910402P 2002-03-29 2002-03-29
US60/369,104 2002-03-29

Publications (1)

Publication Number Publication Date
CN1642543A true CN1642543A (zh) 2005-07-20

Family

ID=28791924

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038073471A Pending CN1642543A (zh) 2002-03-29 2003-03-21 治疗糖尿病性足部感染的噁唑烷酮肠胃外、静脉内和口服给药

Country Status (16)

Country Link
US (1) US20030216330A1 (https=)
EP (1) EP1490059A1 (https=)
JP (1) JP2005527575A (https=)
KR (1) KR20040095328A (https=)
CN (1) CN1642543A (https=)
AU (1) AU2003223334A1 (https=)
BR (1) BR0308806A (https=)
CA (1) CA2476545A1 (https=)
IL (1) IL164195A0 (https=)
MX (1) MXPA04009356A (https=)
NO (1) NO20044672L (https=)
NZ (1) NZ535648A (https=)
PL (1) PL372661A1 (https=)
RU (1) RU2354372C2 (https=)
WO (1) WO2003084534A1 (https=)
ZA (1) ZA200407734B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200404069A (en) * 2002-06-28 2004-03-16 Upjohn Co Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent
JP4579502B2 (ja) * 2003-05-02 2010-11-10 キヤノン株式会社 構造体及びその製造方法、該構造体を含むトナー並びにそれを用いた画像形成方法及び装置
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
JP5043428B2 (ja) 2003-06-03 2012-10-10 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリール複素環式化合物ならびにその製造および使用方法
AR046782A1 (es) * 2003-12-17 2005-12-21 Rib X Pharmaceuticals Inc Compuestos heterociclicos de biarilo halogenados, composiciones farmaceuticas que los contienen, metodos para su elaboracion y su uso como medicamentos.
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
PE20060619A1 (es) * 2004-07-29 2006-07-11 Ferrer Int Derivados de oxazolidinona como antibacterianos
DE602006019870D1 (de) 2005-06-08 2011-03-10 Rib X Pharmaceuticals Inc Verfahren zur synthese von triazolen
EP1745784A1 (en) * 2005-06-27 2007-01-24 Ferrer Internacional, S.A. Oxazolidinone derivatives and use thereof as antibiotics
WO2007000644A1 (en) 2005-06-29 2007-01-04 Pharmacia & Upjohn Company Llc Homomorpholine oxazolidinones as antibacterial agents
US9427468B2 (en) * 2007-08-22 2016-08-30 Trustees Of Dartmouth College Compositions and methods for diagnosing and treating community-acquired methicillin-resistant Staphylococcus aureus
UY32493A (es) * 2009-03-16 2010-10-29 Astrazeneca Ab " (5r)-3-[4-[1-[(2s)-2,3-dihidroxipropanoil]-3,6-dihidro-2h-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, sus sales farmacéuticamente aceptables, sus ésteres hidrolizables y aplicaciones"
US9795601B2 (en) * 2010-12-15 2017-10-24 Biovista, Inc. Compositions and methods for cancer treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705799A (en) * 1983-06-07 1987-11-10 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents
US5043443A (en) * 1988-07-29 1991-08-27 Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5182403A (en) * 1988-09-15 1993-01-26 The Upjohn Company Substituted 3(5'indazolyl) oxazolidin-2-ones
US5225565A (en) * 1988-09-15 1993-07-06 The Upjohn Company Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
ATE146783T1 (de) * 1991-11-01 1997-01-15 Upjohn Co Substituierte aryl- und heteroaryl- phenyloxazolidinone
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
EP0673370B1 (en) * 1992-12-08 1998-01-07 PHARMACIA & UPJOHN COMPANY Tropone-substituted phenyloxazolidinone antibacterial agents
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
EP0730591B1 (en) * 1993-11-22 1999-07-14 PHARMACIA & UPJOHN COMPANY Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425609A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE19514313A1 (de) * 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
BR9509673A (pt) * 1994-11-15 1997-09-30 Upjohn Co Compostos e uso dos mesmos
HRP960159A2 (en) * 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
RU2175324C2 (ru) * 1995-09-01 2001-10-27 Фармация Энд Апджон Компани Фенилоксазолидиноны, имеющие с-с-связь с 4-8-членными гетероциклическими кольцами
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
KR20010015910A (ko) * 1998-01-23 2001-02-26 로렌스 티. 마이젠헬더 옥사졸리디논 조합 라이브러리, 조성물 및 제조 방법
MY122454A (en) * 1998-06-05 2006-04-29 Upjohn Co Use of oxazolidinones for the preparation of a medicament for transdermal delivery
ES2245698T3 (es) * 2000-06-30 2006-01-16 PHARMACIA & UPJOHN COMPANY LLC Composiciones para el tratamiento de infecciones bacterianas que contienen un compuesto de oxazolidinona, sulbactam y ampicilina.

Also Published As

Publication number Publication date
NZ535648A (en) 2007-05-31
PL372661A1 (en) 2005-07-25
CA2476545A1 (en) 2003-10-16
AU2003223334A1 (en) 2003-10-20
KR20040095328A (ko) 2004-11-12
EP1490059A1 (en) 2004-12-29
WO2003084534A1 (en) 2003-10-16
US20030216330A1 (en) 2003-11-20
RU2004131830A (ru) 2005-04-10
BR0308806A (pt) 2005-01-04
MXPA04009356A (es) 2005-01-25
ZA200407734B (en) 2005-06-24
IL164195A0 (en) 2005-12-18
NO20044672L (no) 2004-12-23
RU2354372C2 (ru) 2009-05-10
JP2005527575A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
EP1294717B1 (en) A thiazine oxazolidinone
CN1301751C (zh) 抗感染的医用器材
JP5543932B2 (ja) Ｃｅｔｐ阻害薬
CN1642543A (zh) 治疗糖尿病性足部感染的噁唑烷酮肠胃外、静脉内和口服给药
JP2004501965A (ja) 細菌感染を治療するための組成物および方法
US6927229B2 (en) Difluorothioacetamides of oxazolidinones as antibacterial agents
CN1633292A (zh) 噁唑烷酮与维生素b的联用疗法
HK1075009A (en) Parenteral, intravenous and oral administration of oxazolidinones for treating diabetic foot infections
CN102190656B (zh) 含有五元杂环的噁唑烷酮抗菌素
CN101619061A (zh) 氰基吡啶基取代的噁唑烷酮类化合物
CN1406237A (zh) 新型苯并磺内酰胺噁唑烷酮抗菌剂
US20050075382A1 (en) N-Aryl-2-cyanooxazolidinones and their derivatives
CN115677679A (zh) 含联芳基腙结构的噁唑烷酮化合物及其制备方法和应用
CN1091429A (zh) 内酰胺衍生物
TW200404069A (en) Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent
HK1073794A (en) Cotherapy with an oxazolidinone and a vitamin b
CN1469744A (zh) 含奥沙培南-3-羧酸的药物组合物
CN101096369A (zh) 含噻二唑基的噁唑烷酮化合物及制备方法
HK1055737A (en) A thiazine oxazolidinone
CN1687075A (zh) 3－苯基异噁唑－5－甲酰胺基取代β－内酰胺类衍生物及其用途
MXPA01002980A (es) Tratamiento de infecciones del tracto urinario con oxazolidinonas antibacterianas
ZA200209575B (en) A thiazine oxazolidinone.
TW200305414A (en) β 3 -Adrenergic receptor agonist salt, formulations, and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075009

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075009

Country of ref document: HK